Keywords: GW Pharma, Almirall, Sativex, Mexico, Milestone, Cancer pain

GW Pharma and Almirall extend Sativex deal to Mexico

Article | 15 March 2012

Print This

UK-based GW Pharmaceuticals (AIM: GWP) announces that it has signed an amendment to its cannabis-based drug Sativex licence agreement with ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in